{"id":35839,"date":"2018-05-08T10:29:24","date_gmt":"2018-05-08T08:29:24","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=35839"},"modified":"2018-05-27T11:31:33","modified_gmt":"2018-05-27T09:31:33","slug":"accordo-raggiunto-la-giapponese-takeda-compra-lirlandese-shire-per-52-miliardi","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/accordo-raggiunto-la-giapponese-takeda-compra-lirlandese-shire-per-52-miliardi\/","title":{"rendered":"Agreement reached. Japanese Takeda buys Irish Shire for 52 billion"},"content":{"rendered":"<h1>Pharmaceuticals, maxi-acquisition of the Japanese Takeda: buy the Irish Shire for 52 billion<\/h1>\n<p>It is a record for a Japanese operation. So the company that has more than two centuries of life focuses on rare diseases and development in <a href=\"http:\/\/www.fedaiisf.it\/wp-content\/uploads\/2018\/03\/BF-classifica-fatturato-Takeda-Shire26.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-35395 alignright\" src=\"http:\/\/www.fedaiisf.it\/wp-content\/uploads\/2018\/03\/BF-classifica-fatturato-Takeda-Shire26.jpg\" alt=\"\" width=\"463\" height=\"443\" srcset=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2018\/03\/BF-classifica-fatturato-Takeda-Shire26.jpg 700w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2018\/03\/BF-classifica-fatturato-Takeda-Shire26-300x287.jpg 300w\" sizes=\"auto, (max-width: 463px) 100vw, 463px\" \/><\/a>North America, launching the challenge to the two big USA Pfizer and AbbVie.<\/p>\n<p>The Japanese pharmaceutical company Takeda has reached an agreement to acquire the Irish Shire Plc for 46 billion pounds, the equivalent of 52 billion euros: this is the largest foreign acquisition by a Japanese company. On April 25, Takeda had decided to make a fifth increase attempt by deciding to postpone the expiry of the offer to May 8.<\/p>\n<p>(\u2026 continue on <a href=\"http:\/\/www.repubblica.it\/economia\/finanza\/2018\/05\/08\/news\/farmaceutica_maxi-acquisizione_della_giapponese_takeda_compra_l_irlandese_shire_per_52_miliardi-195808317\/\" target=\"_blank\" rel=\"noopener\">La Repubblica Economy &amp; Finance of 8 May 2018<\/a>)<\/p>\n<p>Related news:\u00a0<a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2018-05-08\/takeda-inks-62-billion-deal-to-buy-shire-for-cash-and-shares\" target=\"_blank\" rel=\"noopener\">Takeda Clinches $62 Billion Deal to Buy Drugmaker Shire<\/a><\/p>\n<p><a href=\"https:\/\/www.pharmastar.it\/news\/business\/aurobindo-offre-16-mld-per-acquisire-i-generici-dermatologici-di-novartis-26696\" target=\"_blank\" rel=\"noopener\">Aurobindo offers $1.6 billion for Novartis dermatological generics<\/a><\/p>\n<p><a href=\"https:\/\/www.adviseonly.com\/blog\/economia-e-mercati\/politica-e-societa\/le-big-pharma-si-difendono-con-brevetti-e-acquisizioni\/\" target=\"_blank\" rel=\"noopener\">Big Pharma defends itself with patents and acquisitions<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Farmaceutica, maxi-acquisizione della giapponese Takeda: compra l&#8217;irlandese Shire per 52 miliardi E&#8217; record per un&#8217;operazione nipponica. Cos\u00ec la societ\u00e0 che ha oltre due secoli di vita punta sulle malattie rare e lo sviluppo in Nordamerica, lanciando la sfida ai due big Usa Pfizer e AbbVie. L&#8217;azienda farmaceutica giapponese Takeda ha raggiunto un accordo per rilevare &hellip;<\/p>","protected":false},"author":4,"featured_media":35394,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[53],"class_list":["post-35839","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-primo-piano","tag-fusioniacquisizioni"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/35839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=35839"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/35839\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/35394"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=35839"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=35839"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=35839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}